statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
SLS stock results show that SELLAS Life Sciences Gr missed analyst estimates for earnings per share the fourth quarter of 2023.
The post...

SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib) Treating...

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib) Treating Diffuse Large B Cell Lymphoma

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Sellas Life Sciences files to sell 13.03M shares of common stock for holders

Sellas Life Sciences files $200M mixed securities shelf

Sellas Life Sciences reports 2023 EPS ($1.34), consensus ($1.08)

Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified...

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Sellas Life Sciences announces data from Phase 2a study of SLS009

- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April - - Phase 2a study of SLS009 in r/r AML: 50% Response...

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Sellas Life Sciences options imply 20.1% move in share price post-earnings

- Update on the Phase 3 REGAL Clinical Trial of GPS in Acute Myeloid Leukemia (AML) - - Update on the Phase 2a Clinical Trial of SLS009 in relapsed/refractory AML, including topline data - NEW...

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Watchers	43,595
52-Wk Low	$0.4986
52-Wk High	$1.91

Volume	711,112.00
52-Wk High	$1.91
52-Wk Low	$0.4986

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.16	--	--	N/A
Q4'23	$0.09	-$0.23	-365.38%	MISSED
Q3'23	$0.02	-$0.33	-1985.71%	MISSED
Q2'23	-$0.36	-$0.31	12.68%	BEAT
Q1'23	-$0.29	-$0.47	-62.07%	MISSED

SLS SELLAS Life Sciences Group Inc

About

Feed

News

Earnings

Fundamentals